title: Reply to: "Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives" Inflammopharmacology DOI:10.1007/s10787-014-0202-3.
abstract: This is a reply to a recently published Commentary: "Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives" Inflammopharmacology DOI: 10.1007/s10787-014-0202-3 , written in relation to our review article: Skaper SD, Facci L, Fusco M, della Valle MF, Zusso M, Costa B, Giusti P (2014) "Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain" Inflammopharmacology 22:79-94 DOI: 10.1007/s10787-013-0191-7 . We believe that the Commentary by Kriek contains a number of erroneous statements and misinterpretations of the published scientific/medical literature which our reply shall elaborate on. Further, the writer of the Commentary has a direct connection to a company, JP Russell Science Ltd that sells palmitoylethanolamide. The take-home message of our review remains as originally stated: "Collectively, the findings presented here propose that palmitoylethanolamide merits further consideration as a disease-modifying agent for controlling inflammatory responses and related chronic and neuropathic pain".
authors.affiliation: University of Padua, Padua, Italy, stephen.skaper@unipd.it.
authors.forename: Stephen D
authors.initials: SD
authors.lastname: Skaper
authors.forename: Laura
authors.initials: L
authors.lastname: Facci
authors.forename: Mariella
authors.initials: M
authors.lastname: Fusco
authors.forename: Maria Federica
authors.initials: MF
authors.lastname: Della Valle
authors.forename: Morena
authors.initials: M
authors.lastname: Zusso
authors.forename: Barbara
authors.initials: B
authors.lastname: Costa
authors.forename: Pietro
authors.initials: P
authors.lastname: Giusti
mesh_terms: D000818:Animals; D063388:Endocannabinoids / Q000494:pharmacology* / Q000627:therapeutic use*; D004983:Ethanolamines / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D009437:Neuralgia / Q000188:drug therapy*; D010169:Palmitic Acids / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D063388:Endocannabinoids; D004983:Ethanolamines; D010169:Palmitic Acids